Division of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece.
Laboratory of Virology & Chemotherapy, Rega Institute, KU Leuven, 3000 Leuven, Belgium.
Molecules. 2020 Oct 3;25(19):4531. doi: 10.3390/molecules25194531.
The strong inhibition of Human Cytomegalovirus (HCMV) replication by benzimidazole nucleosides, like Triciribine and Maribavir, has prompted us to expand the structure-activity relationships of the benzimidazole series, using as a central core the imidazo[4,5-b]pyridine scaffold. We have thus synthesized a number of novel amino substituted imidazopyridine nucleoside derivatives, which can be considered as 4-(or 7)-aza-d-isosters of Maribavir and have evaluated their potential antiviral activity. The target compounds were synthesized upon glycosylation of suitably substituted 2-aminoimidazopyridines, which were prepared in six steps starting from 2-amino-6-chloropyridine. Even if the new compounds possessed only a slight structural modification when compared to the original drug, they were not endowed with interesting antiviral activity. Even so, three derivatives showed promising cytotoxic potential.
苯并咪唑核苷(如曲昔匹特和马拉维若)对人巨细胞病毒(HCMV)的强烈抑制作用促使我们扩展了苯并咪唑系列的构效关系,以咪唑并[4,5-b]吡啶为核心骨架。因此,我们合成了一些新型的氨基取代的咪唑并吡啶核苷衍生物,它们可以被视为马拉维若的 4-(或 7)-氮杂-d-异甾体,并评估了它们的潜在抗病毒活性。目标化合物是通过适当取代的 2-氨基咪唑并吡啶的糖苷化合成的,该化合物是从 2-氨基-6-氯吡啶开始分六步合成的。尽管与原始药物相比,新化合物仅进行了轻微的结构修饰,但它们并没有表现出有趣的抗病毒活性。尽管如此,有三个衍生物显示出有希望的细胞毒性潜力。